Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001071789 | SCV001237110 | likely benign | Tuberous sclerosis 1 | 2024-07-08 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV002307679 | SCV002009249 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001071789 | SCV002039275 | uncertain significance | Tuberous sclerosis 1 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002307679 | SCV002601392 | uncertain significance | not provided | 2022-05-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004678953 | SCV005173434 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-16 | criteria provided, single submitter | clinical testing | The p.G443R variant (also known as c.1327G>A), located in coding exon 11 of the TSC1 gene, results from a G to A substitution at nucleotide position 1327. The glycine at codon 443 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |